BCM
CCCC icon

Bronte Capital Management’s C4 Therapeutics CCCC Stock Holding History

Bronte Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4K Hold
10,033
– – ﹤0.01% 49
2025
Q4 		$19.2K Buy
+10,033
New +$23.8K ﹤0.01% 44

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bronte Capital Management's CCCC Position: Q1 2026 in Review

Bronte Capital Management held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 10,033 shares worth $26.4K. The position accounts for ﹤0.01% of the portfolio, ranked #49.

Bronte Capital Management first reported a position in CCCC in Q4 2025 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Bronte Capital Management held 10,033 shares of C4 Therapeutics worth $26.4K as of Q1 2026.
  • Bronte Capital Management left its C4 Therapeutics share count unchanged in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Bronte Capital Management's portfolio in Q1 2026, its #49 holding.
  • Bronte Capital Management first reported a position in C4 Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.